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BACKGROUND: Invasion and metastases of cancer cells and the development of resistance to anticancer therapies are the main causes
of treatment failure and mortality in cancer patients.
METHODS: We evaluated invasive markers of urokinase plasminogen activator (uPA) and CD44 and multiple drug-resistance (MDR)
markers of MDR1 and MRP2 in four epithelial ovarian cancer (EOC) cell lines, primary tumours (n¼120) and matched metastatic
lesions (n¼40) by immunofluoresence labelling. We correlated uPA and CD44 with MDR markers in primary and metastatic cells
using confocal microscope. We also investigated the relationship of the expression of uPA, CD44 and MDR1 with various
progression parameters.
RESULTS: The coexpression of uPA and CD44 with MDR markers was found in primary and metastatic cells. The overexpression of
uPA, CD44 and MDR1 was found in most primary and matched metastatic lesions of EOC, and was significantly associated with
tumour stage, grade, residual disease status, relapse and presence of ascites (Po0.05), but not with histology type (P40.05).
CONCLUSIONS: Our results suggest that the overexpression of uPA, CD44 and MRD1 is correlated with EOC progression; both
uPA and CD44 are related with drug resistance during EOC metastasis and could be useful therapeutically.
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Ovarian cancer is one of the most fatal malignancies. The standard
treatment for advanced ovarian cancer is surgical removal of
tumour, followed by platinum-based chemotherapy. Although
patients may initially respond to chemotherapy, many still relapse,
develop drug resistance and ultimately succumb to the disease
(Bhoola and Hoskins, 2006). There is indirect evidence that the
phenotypes between metastasis and multiple drug resistance
(MDR) may be functionally linked. However, the relationship
between them is still unclear.
Urokinase plasminogen activator (uPA) is a member of the
serine protease family and is strongly implicated as a promoter of
tumour progression in various human malignancies. By binding to
uPA receptors (uPAR), uPA efficiently converts the inactive
zymogen, plasminogen, into the active serine protease, plasmin,
which then directly or indirectly cleaves extracellular matrix
(ECM) components including laminin, fibronectin, fibrin, vitro-
nectin and collagen (Andreasen et al, 1997). Plasmin can activate
latent elastase and matrix metalloproteinases, potent enzymes that
can also digest a variety of ECM components (Andreasen et al,
1997). Overwhelming evidence shows that the cell-surface-
associated uPA–uPAR complex is causatively involved in tumour
invasion and metastasis of many types of cancers by exerting
multifaceted functions through either direct or indirect interac-
tions with integrins, endocytosis receptors and growth factors
(Andreasen et al, 1997; Sidenius and Blasi, 2003).
CD44 is a family of cell-surface glycoproteins that are expressed
in a variety of human solid tumours, particularly those of
gynaecological origin (e.g., ovarian cancers) (Naor et al, 1997;
Kayastha et al, 1999), and is implicated in cell adhesion, motility
and metastases (Naor et al, 1997). The gene that encodes CD44
contains 19 exons and is alternatively spliced, giving rise to many
CD44 isoforms. All CD44 isoforms contain a hyaluronic acid (HA)-
binding site in their extracellular domain, which serves as the
major cell-surface receptor for HA (Underhill, 1992).
A major mechanism for drug resistance in cancer is energy-
dependent efflux pumps that reduce intracellular accumulation.
MDR1/P-glycoprotein (P-gp) called as ABCB1, a 170-kDa mem-
brane phosphoglycoprotein encoded by the mdr1 gene (MDR1)
located on chromosome 7q21, is a well-characterised member of
energy-dependent drug efflux pumps (Germann, 1996). MRP2 is a
member of the MRP/ABCC subfamily and also has an important
function in the occurrence of the MDR phenotype in cancer cells
(Kruh and Belinsky, 2003). It has been reported that MRP2 confers
resistance to several other anticancer agents being non-platinum-
containing drugs, including methotrexate, vinblastine and camp-
tothecin derivatives (Cui et al, 1999).
A correlation between the expression of MDR1 and CD44 has
been found in breast cancer cell lines, which showed that the two
proteins colocalise within the cell membrane, that one protein
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sdirectly influences the expression of the other and that a disruption
of this interaction has profound effects on drug resistance, cell
migration and in vitro invasion (Miletti-Gonzalez et al, 2005).
Specifically, HA binding to CD44 is capable of stimulating MDR1
expression and drug resistance in breast tumour cells through ErbB2
signalling and PI3 kinase/Akt-related survival pathways (Misra et al,
2005). Bourguignon et al (2008) have recently shown that HA–CD44
interaction activates stem cell marker Nanog, Stat-3-mediated MDR1
gene expression and ankyrin-regulated multidrug efflux in breast
and ovarian tumour cells. However, a direct link of phenotypes
between drug resistance and invasion or metastasis in epithelial
ovarian cancer (EOC) is still unclear.
The purpose of this study was to investigate whether a linkage
exists between metastatic potential markers (uPA, CD44) and MDR
proteins (MDR1, MRP2) during EOC progression. We found a
colocalisation of uPA, CD44, MDR1 and MRP2 in primary and
metastatic EOC cells lines. We showed that overexpression of uPA,
CD44 and MRD1 is correlated with EOC progression. In addition,
we further confirmed the colocalisation of uPA, CD44 and MDR1
in primary and metastatic lesions of EOC tissues. Our results
suggest that uPA and CD44 are related to drug resistance and
could be useful therapeutic targets for the prevention of the
development of incurable, recurrent and drug-resistance EOC.
MATERIALS AND METHODS
Antibodies
The following antibodies were used: mouse anti-human uPA IgG1
(no. 394) (American Diagnostica, Greenwich, CT, USA); rabbit
anti-human CD44 monoclonal antibody (MAb) (ab51037) and
rabbit anti-human uPA (ab24121) polyclonal antibody (Abcam,
Cambridge, UK); mouse anti-human CD44 and mouse anti-human
IgG1-negative control MAbs (Dako, Glostrup, Denmark); rabbit
anti-human MDR1 polyclonal antibody (sc-1517-R) (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA); mouse anti-hu-
manMRP2 (M2III-6) MAb (Alexis Biochemicals, San Diego, CA,
USA); and Alexa Fluor-488 goat anti-mouse IgG and Alexa Fluor-
594 goat anti-rabbit IgG (Molecular Probes, Eugene, OR, USA).
Cell lines and cell culture
The primary (OVCAR-3, A2780) and metastatic (SKOV-3, OV-90)
EOC cell lines were obtained from American Type Culture Collection
(ATCC, Rockville, MD, USA). All tissue culture reagents were
supplied by Invitrogen Australia Pty Ltd (Melbourne, VIC, Australia),
unless otherwise stated. OVCAR-3, A2780 and SKOV-3 cells were
cultured in RPMI-1640 supplementedw i t h1 0 %( v / v )h e a t - i n a c t i v a t e d
fetal bovine serum (FBS), 50Uml
 1 penicillin and 50Uml
 1
streptomycin. OV-90 cells were maintained in a 1:1 mixture of
MCDB 105 medium (Sigma-Aldrich, St Louis, MO, USA) and 199
medium (Sigma-Aldrich), supplemented with 15% FBS, 50Uml
 1
penicillin and 50Uml
 1 streptomycin. All cell lines were maintained
in a humidified incubator at 371Ca n d5 %C O 2. Subconfluent cells
that had been in culture for 48h without a change of medium were
harvested by gently rinsing flasks twice with Dulbecco’s phosphate-
buffered saline and then detached with 0.25% trypsin/0.05% EDTA in
phosphate-buffered saline at 371C. Cells were collected and
resuspended in the appropriate buffer as described above.
Immunofluorescence confocal microscopy analysis
To determine the cellular localisation of uPA, CD44, MDR1 and
MRP2 in EOC cells, OVCAR-3, A2780, SKOV-3 and OV-90 cells
were grown on glass coverslips (10
5 cells) for 24h. After washing
with Tris-buffered saline (TBS) (pH 7.5), the cells were fixed on
coverslips in ice-cold methanol for 10min at room temperature
(RT) and then incubated with 10% normal goat serum in TBS for
20min to suppress the nonspecific binding of IgG. After washing
once again with TBS, the cells were incubated with mouse anti-uPA
(1:300 dilution) or rabbit anti-uPA (1:300 dilution), mouse anti-
CD44 (1:50 dilution) or rabbit anti-CD44 (1:300 dilution), anti-
MDR1 (1:300 dilution) and anti-MRP2 (1:50 dilution) antibodies
for 1h at RT on a shaking table and rinsed with TBS, followed by a
45min incubation with Alexa Fluor-conjugated anti-mouse or
anti-rabbit IgG (1:1000 dilution) for 1h at RT. The stained cells
were mounted on glass slides using glycerol (Sigma-Aldrich Pty
Ltd, Castle Hills, NSW, Australia). Examination was performed
with Confocal Microscope (FV 300/FV500 Olympus, Tokyo, Japan).
Negative control slides were treated identically by isotype control
MAbs or the primary antibody was omitted as a negative control.
Patients and clinical data
A total of 120 primary EOC and 40 corresponding intraperitoneal
metastatic lesions were obtained from the surgical pathology files
of the Department of Pathology, Henan Tumour Hospital, China.
All patients underwent primary surgery at the Department of
Gynecological Oncology between 2001 and 2007. None of the
patients had received chemotherapy before surgery. Clinical data
were obtained by a retrospective review of the medical records.
The study was approved by the Institutional Review Board, Henan
Tumour Hospital. Tumours were staged according to the criteria of
the International Federation of Gynecology and Obstetrics (FIGO)
(Creasman, 1989). Details of the patients’ characteristics are
summarised in Table 1. Twenty normal ovarian specimens
(controls) were obtained from early-stage cervical cancer patients
with a mean age of 51±14 years (range, 40–70), who underwent
surgery during the same period (Table 1). The criteria for tumour
Table 1 The characteristics of primary EOC patients
EOC patients Control subjects
Number of patients 120 20
Age mean±s.d. (years) 53±18 51±14
Range 45–76 40–70
Grading
Grade 1 18 (15%)
Grade 2 35 (29%)
Grade 3 67 (56%)
Clinical stage (FIGO) No. (%)
I 9 (7%)
II 25 (21%)
III 80 (67%)
IV 6 (5%)
Histology
Serous 70 (58%)
Mucinous 23 (19%)
Undifferentiated 11 (9%)
Endometrioid 8 (7%)
Clear cell 8 (7%)
Residual tumour after the first surgery
No 68 (57%)
Yes 52 (43%)
Relapse
No 33 (28%)
Yes 87 (72%)
Ascites
No 22 (18%)
Yes 98 (82%)
EOC¼epithelial ovarian cancer; FIGO¼Federation of Gynecology and Obstetrics
(Creasman, 1989).
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srelapse were serum levels of CA125 435mgml
 1, which continued
to increase, with confirmation by B ultrasound, computed
tomography, magnetic resonance imaging or positron emission
tomography.
Tumour tissue collection
Surgical specimens (EOC tissues and normal ovarian tissues) were
fixed in 10% neutral-buffered formalin, routinely processed,
whole-mount-embedded in paraffin and 4mm sections were
collected. Haematoxylin and eosin (H&E)-stained sections were
examined and tumour foci were identified, circled in ink and
graded. All tissue specimens from primary tumours and metastatic
lesions were verified by histology to confirm diagnosis, histological
type and tumour grade (Dr QingKai Yu, Pathologist, Director of
Department of Pathology, Henan Tumour Hospital, China).
Immunofluorescence staining on EOC tissues
For the expression of uPA, CD44 and MDR1, sections including
primary and metastatic tumours were deparaffinised in xylene and
dehydrated in a graded series of alcohol (100, 95 and 75%) and
rehydrated in TBS. Antigen retrieval was performed in a boiling
citrate buffer (0.01 M, pH 6.0) for 20min. Thereafter, the sections
were incubated with normal goat serum (1:10 dilution) for 10min
and then incubated overnight with mouse anti-uPA MAbs no. 394
(1:100 dilution), mouse CD44 (1:50 dilution) and rabbit MDR1
(1:200 dilution) at 41C. After washing with TBS, the slides were
incubated with Alexa Fluor 488 goat anti-mouse IgG (1:1000
dilution) or Alexa Fluor 594 goat anti-rabbit IgG (1:1000 dilution)
in the dark for 45min at RT, and then mounted with Gleracol
(Sigma-Aldrich). Negative control slides were treated identically,
but isotype control MAbs (mouse anti-human IgG1) were used or
the primary antibody was omitted as a negative control. The PC-3
prostate cancer cell line (uPA, CD44 and MDR1 positive) was used
as a positive control.
For colocalisation of uPA, CD44 and MDR, sections including
primary and metastatic tumours were incubated overnight at 41C
in primary mouse anti-uPA (no. 394) (1:100 dilution) and mouse
CD44 (1:50 dilution) MAbs; and rabbit anti-uPA (1:100 dilution)
and rabbit anti-human MDR1 (1:300 dilution) polyclonal
antibodies, respectively. After washing with TBS, the sections were
incubated in goat anti-mouse Alexa 488 (for mouse uPA and
CD44) and goat anti-rabbit Alexa 594 (for rabbit uPA and MDR1)
for 1h at RT, and rinsed in TBS. Controls were treated identically,
using nonspecific immunoglobulins (IgG1 or rabbit IgG) as
negative control. The sections were examined using a Zeiss LSM
5 Pascal laser scanning confocal microscope and LSM 5 Pascal
Image software. Multichannel excitation bleedthrough was mini-
mised using fluorochromes with a large difference in peak
excitation (488 and 594nm, respectively). Examination was
performed with a confocal microscope (FV 300/FV500 Olympus,
Tokyo, Japan). Multitracking and sequential image capture was
used to correct signal emission crosstalk between neighbouring
channels, and the images were combined.
Assessment of immunofluoresence staining results
Immunostaining results were assessed by staining intensity (0–3)
for tested cancer cell lines and tissues. The criteria used for
assessment were as follows: 0, negative or o25% tumour stained;
1þ, weak or 25–50% tumour stained; 2þ, moderate or 50–70%
tumour stained; and 3þ, strong or 475% tumour stained.
Immunostaining was carried out independently by two experi-
enced observers (HC and YL), and specimens were scored blindly
and averaged. If results were discordant, differences were resolved
by joint review and consultation with other experienced observers.
For statistical analysis, EOC cases were divided into two groups:
the low-expression group (LEG), composed of the   and 1þ
groups, and the high-expression (overexpression) group (HEG),
composed of the 2þ and 3þ groups.
Statistical analysis
The associations between uPA, CD44 and MDR1 expression levels
(LEG and HEG) and clinicopathological data were tested using the
w
2-test. Comparison of staining intensity for uPA, CD44 and MDR1
between EOC tissues and normal ovarian tissues or between
primary EOC and metastatic lesions was carried out using the w
2-
test, where Po0.05 (two-tail) was considered significant. All
statistical analyses were performed using GraphPad Prism 4.00
(GraphPad, San Diego, CA, USA).
RESULTS
Expression and colocalisation of uPA, CD44, MDR1 and
MRP2 in primary and metastatic EOC cell lines
Immunofluorescence labelling results of EOC cells with uPA,
CD44, MDR1 and MRP2 antibodies showed positive staining in all
cancer cell lines (Figures 1 and 2). The staining intensities are
summarised in Table 2. All EOC cell lines express medium to high
levels of uPA, CD44, MDR1 and MRP2. Membrane expression was
found in CD44 antibodies, whereas both membrane and cytoplasm
expressions were found in uPA, MDR1 and MRP2 antibodies. The
staining pattern is more homogeneous. Colocalisation of uPA/
CD44, uPA/MDR1, uPA/MRP2, CD44/MDR1 and CD44/MRP2 was
observed in all tested primary and metastatic cell lines (Figures 1
and 2).
Expression of uPA, CD44 and MDR1 in primary EOC
tissues and metastatic lesions
In primary EOC tissues, 88% (105 out of 120), 83% (100 out of 120)
and 80% (96 out of 120) were positive to uPA, CD44 and MDR1
(1þ to 3þ), respectively, whereas in the matched metastatic
lesions, 90% (36 out of 40), 85% (34 out of 40) and 83% (33 out of
40) were positive to uPA, CD44 and MDR1 (1þ to 3þ),
respectively. Of the uPA-positive EOC sections, weak staining
(1þ) was found in 15% (16 out of 105) (Figure 3A), moderate
staining (2þ) in 45% (47 out of 105) (Figure 3D) and strong
staining (3þ) in 40% (42 out of 105) in primary tumours, whereas
weak staining was found in 19% (7 out of 36), moderate staining in
44% (16 out of 36) and strong staining in 36% (13 out of 36)
(Figure 3G) in metastatic lesions.
Of the CD44-positive sections, weak staining (1þ) was found in
26% (26 of 100) (Figure 3B), moderate staining (2þ) in 43% (43 of
100) (Figure 3E) and strong staining (3þ) in 31% (31 of 100) in
primary tumours, whereas weak staining (1þ) was found in 20%
(8 of 40), moderate staining (2þ) in 35% (14 of 40) and strong
staining (3þ) in 30% (12 of 40) (Figure 3H) in metastatic lesions.
Of the MDR1-positive sections, weak staining (1þ) was found
in 21% (20 of 96) (Figure 3C), moderate staining (2þ) in 44% (42
of 96) (Figure 3F) and strong staining (3þ) in 35% (34 of 96) in
primary tumours, whereas weak staining (1þ) was found in 20%
(8 of 40), moderate staining (2þ) in 35% (14 of 40) and strong
staining (3þ) in 28% (11 of 40) (Figure 3I) in metastatic lesions.
No uPA, CD44 and MDR1 staining was found in normal ovarian
tissues and negative sections from primary EOC tissues and
metastatic lesions (data not shown). The staining intensity for uPA,
CD44 and MDR1 in primary and metastatic lesions is summarised in
Table 3, which shows the relationship of uPA, CD44 and MDR1
staining in two groups (primary and metastatic tumours). The
concordance rate of uPA, CD44 and MDR1 was 87–90% in primary
EOC and metastatic lesions. The primary tumours from patients with
uPA, CD44 and MDR1-positive metastatic lesions also expressed uPA,
uPA, CD44 and MDR proteins in ovarian cancer
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strong in this group of patients.
The expression of uPA, CD44 and MDR1 was quite uniform in
most tumours, and regions of heterogeneous staining were rarely
seen. The expression of uPA and CD44 was mainly cell membrane
associated; however, distinct positive cytoplasmic staining was also
observed. Immunostaining of MDR1 was mainly cell cytoplasmic
staining. In high-grade EOC (Grade 2 and 3), the most tumour
stroma also showed a strong positive reaction for uPA, CD44 and
MDR1 in primary tumours and metastatic lesions (data not shown).
Correlation between clinical parameters and uPA, CD44
and MDR1 expression
Of the 120 EOC patients, 72% (87 of 120) relapsed with metastases.
The median time to relapse was 42 months (range, 15–56 months).
Overall, 52% of patients had residual tumours after first surgery
and 82% of patients had ascites of more than 500ml. Table 4
summarises the correlation among uPA, CD44 and MDR1 expres-
sions in primary tumours with tumour grade, clinical stage,
histological type, residual tumour after first surgery, relapse and
ascites. The overexpression (HEG) of uPA, CD44 and MDR1 was
correlated with relapse (Po0.01) and increased with the progres-
sion of EOC (tumour grade, Po0.01; clinical stage, Po0.05;
residual tumour after first surgery, Po0.05; ascites, Po0.05).
There was no correlation between the overexpression of uPA,
CD44 and MDR1 and histological type.
Coimmunolabelling of primary tumours and metastatic
lesions with uPA, CD44 and MDR1 antibodies
Colocalisation of uPA and CD44, uPA and MDR1, CD44 and MDR1
was further tested in primary tumours and matched metastatic
lesions (n¼40). Most of the tested samples were found to be
MRP2
uPA+MRP2
OVCAR-3
uPA
A2780 SKOV-3 OV-90
CD44
uPA+CD44
CD44+MDR1
MDR1
Figure 1 Coimmunolabelling of uPA, CD44, MDR1 and MRP2 in EOC. Representative confocal images of uPA and MDR1 (red; Alexa-594), and CD44
and MRP2 (green; Alexa-488) expression in EOC primary and metastatic cell lines are shown. Merged images, and red and green channels are shown
separately. (A) uPA expression; (B) CD44 expression; (C) MDR1 expression; (D) MRP2 expression; (E) Colocalisation of uPA with CD44; (F)
Colocalisation of uPA with MRP2; (G) Colocalisation of CD44 with MDR1. Magnification: A–G  400.
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staining in different samples was variable. The typical images from
different tumours are shown in Figure 4. For coimmunolabelling of
uPA with CD44 (Figure 4A and B) and of uPA with MDR1 (Figure
4C and D), uPA appears green, whereas CD44 and MDR1 appear
red. For coimmunolabelling of CD44 with MDR1 (Figure 4E and
F), CD44 appears green, whereas MDR1 appears red.
DISCUSSION
Invasion and metastases of cancer cells and the development of
resistance to antidrug therapies are the main causes of morbidity
and mortality from cancer. Proteolytic enzymes such as uPA
system and CD44 have an active function in EOC metastasis. Drug-
resistance proteins such as MDR1 and MRP2 are the best-known
mediators of resistance to anticancer drugs, extruding many types
of drugs from cancer cells, thereby conferring resistance to those
agents. Although previous reports have shown that the presence of
uPA, CD44 and MDR proteins was related to EOC progression and
prognosis (Kayastha et al, 1999; Konecny et al, 2001; Penson et al,
2004), their expression and link between these two markers in
primary EOCs and in metastatic microenvironment have not been
fully investigated.
In this study, we examined the expression of uPA, CD44, MDR1
and MRP2 in EOC cell lines, in primary EOC, matched metastatic
uPA+MDR1
CD44+MRP2
OVCAR-3 A2780 SKOV-3 OV-90
uPA
MDR1
CD44
MRP2
Control
Figure 2 Coimmunolabelling of uPA, CD44, MDR1 and MRP2 in EOC. Representative confocal images of uPA and MRP2 (green; Alexa-488), and CD44
and MDR1 (red; Alexa-594) expression in EOC primary and metastatic cell lines are shown. Merged images, and red and green channels are shown
separately. (A) uPA expression; (B) CD44 expression; (C) MDR1 expression; (D) MRP2 expression; (E) Colocalisation of uPA with MDR1; (F)
Colocalisation of CD44 with MRP2; (G) IgG-negative control. Magnification: A–G  400.
uPA, CD44 and MDR proteins in ovarian cancer
H Chen et al
436
British Journal of Cancer (2009) 101(3), 432–440 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
slesions and normal ovarian tissues using tissue bank, and
investigated the link among these markers. High levels of uPA,
CD44, MDR1 and MRP2 were observed in EOC cell lines, in
advanced EOC specimens but not in normal ovarian tissues. Most
of the metastatic lesions and matched primary cancer tissues
expressed high levels of uPA, CD44 and MDR1. Colocalisation of
metastatic markers (uPA, CD44) and MDR proteins (MDR1,
MRP2) was also observed in EOC cells. To our knowledge, this is
the first report investigating the link among uPA, CD44, MDR1
and MRP2 during EOC progression.
One of the interesting findings in this study is the colocalisation
of uPA and CD44, uPA and MDR1, uPA and MRP2, CD44 and
MDR1 or CD44 and MRP2 in primary and metastatic EOC cells.
Kobayashi et al (2002) reported that CD44 stimulation by
fragmented HA can activate MAP kinase (MAPK) proteins and
upregulate the expression of uPA mRNA and protein in human
chondrosarcoma cell line HCS-2/8, which supports the role of uPA
as an invasion-promoting factor. Sheridan et al (2006) showed that
breast cancer cell lines with a significant CD44þ/CD24  sub-
population express higher levels of the uPA gene associated with
cancer invasion (Sheridan et al, 2006). uPA and uPAR are
upregulated in tumours of various origins, wherein they have an
important function in the development of invasive and chemore-
sistant cancer phenotypes (Gutova et al, 2007). The direct link
between uPA and cancer stem cells (CSCs) or MDR proteins has
not been reported. Gutova et al (2008) have recently shown that
uPA can mediate human stem cell tropism to malignant solid
tumours by chemotaxis and cell guidance. Here, we first showed
the colocalisation of uPA and CD44 in primary and metastatic EOC
cells, and the direct link between uPA and MDR proteins (MDR1
and MRP2). These results support the fact that uPA has a close
relationship with CD44, and may be involved in the regulation of
the expression of MDR1 and MRP2 during EOC metastasis.
CD44 is a marker of CSC (Dalerba et al, 2007). Zhang et al
(2008) have recently identified a sub-population of CD44þ
CD117þ cells (ovarian cancer-initiating cells) from primary
ovarian cancer tissues that are fully capable of a serial propagation
of their original tumour phenotype in animals, suggesting that
CD44 is involved in EOC progression. It was reported that
hyaluronan–CD44 interactions regulate the expression of drug
transporters, including P-glycoprotein (MDR1) and MRP2 (Misra
et al, 2005). In this study, we found a direct link of uPA and CD44
with MDR proteins (MDR1and MRP2) in primary and metastatic
EOC cells. In a parallel study, we compared metastatic prostate
cancer cell line (DuCaP), which is negative to uPA, CD44, MDR1
and MRP2, with docetaxel drug-resistant prostate cancer cell line
(PC-3M-Luc-MDR), which is strongly positive to uPA, CD44,
MDR1 and MRP2. After treatment with a chemodrug (docetaxel),
more DuCaP cells were killed compared with PC-3M-luc-MDR
cells (unpublished data). These results suggest that uPA and CD44
may functionally regulate MDR1 or MRP2 expression and confer
drug resistance to ovarian cells during cancer progression, further
confirming the close link between invasive and metastatic markers
(uPA and CD44) with MDR proteins (MDR1 and MRP2), and may
have clinical significance for future therapy to target late-stage and
drug-resistance ovarian cancer cells.
In ovarian cancers, a significant elevation of uPA levels is
associated with prognosis and disease progression (Konecny et al,
Table 2 Inmmunofluoresence staining intensity of uPA, CD44, MDR1
and MRP2 in EOC cell lines
Ovarian cancer cell line
Primary EOC cell line Metastatic EOC cell line
Marker OVCAR-3 A2780 SKOV-3 OV-90
uPA 2 2 3 2–3
CD44 2 2 3 2
MDR1 1–2 2 2 3
MRP2 2 1–2 2 2–3
Notes: Immunofluorescence staining scores: 0¼negative; 1¼weak; 2¼moderate;
3¼strong.
Medium
uPA CD44 MDR1
Low
High
Figure 3 Immunofluoresence staining for uPA, CD44 and MDR1 in
primary and metastatic EOCs. Representative images from different
patients. Representative confocal images of uPA and CD44 (green;
Alexa-488) and MDR1 (red; Alexa-594) expression in EOC primary and
metastatic EOC tissues are shown. Low levels of uPA, CD44 and MDR1
are shown in primary EOC tissues (A–C), respectively. Medium levels of
uPA, CD44 and MDR1 are shown in primary EOC tissues (D–F),
respectively. High levels of uPA, CD44 and MDR1 are shown in metastatic
EOC tissues (G–I), respectively. uPA immunolabelling is homogeneous
and is generally seen on epithelial and stromal cells. Magnification: A–I
 400.
Table 3 uPA, CD44 and MDR1 immunoreactivity in the primary EOC and metastatic lesions
Antigen
uPA (#394 MAb) CD44 (MAb) MDR1 (sc-1517-R Ab)
Specimens
Immunostaining
a %
Pos
b %H E G
c
Immunostaining
a
%Pos
b HEG
c
Immunostaining
a
%Pos
b HEG
c
Score 0 1+ 2+ 3+ 0 1+ 2+ 3+ 0 1+ 2+ 3+
PT (n¼120) 15 16 47 42 88 74 20 26 43 31 83 62 24 20 42 34 80 64
MT (n¼40) 4 7 16 13 90 73 6 8 14 12 85 65 7 8 14 11 83 63
aImmunostaining staining score: 0¼negative; 1+¼weak; 2+¼moderate; 3+¼strong.
b% Immunopositive tumours (score 1+ to 3+) in each subgroup;
c% of tumours Xscore
2+ immunostaining in each subgroup (high-expression group¼HEG); MT¼metastatic tumours; PT¼primary tumours.
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s2001). The increased expression of uPA mRNA is associated with
the dedifferentiation of serous EOC from cystic to solid tumours
(Borgfeldt et al, 2001). The levels of uPA in peripheral blood were
higher in patients with EOC than in controls (Casslen et al, 1994).
The tumour content of uPA was reported to be increased with loss
of histological differentiation and also tended to increase in
advanced FIGO stages in ovarian cancer (Borgfeldt et al, 1998).
This study also indicates that the high level of expression of
uPA was correlated with tumour grade, clinical stage, residual
tumour, relapse and ascites. However, we found no difference in
histological type. These results indicate that uPA has an important
function in EOC development and metastasis.
Induction of CD44 expression has been noted during the
development of EOC, but the issues of whether a high CD44
expression represents a relatively favourable prognosis (Ross et al,
2001) or an aggressive behaviour of the tumour and unfavourable
prognosis (Kayastha et al, 1999), and whether CD44 has any
prognostic significance (Berner et al, 2000), have remained
controversial. Sillanpaa et al, (2003) reported that CD44 expression
is related to well-differentiated, early-stage EOC and long survival
of the patients, thus indicating a favourable prognosis in EOC.
Kayastha et al reported that expression of CD44 is an independent
predictor of survival in women with EOC. Afify et al (2006)
reported that the expression of CD44s and CD44v5 is more
common in stage III than in stage I serous ovarian carcinomas and
suggested a role for CD44 and stromal HA in the dissemination of
EOC. The large variation of the CD44 expression from study to
study may be attributed to the different methodologies used in the
assessment of CD44 expression or to the different stages of ovarian
cancer in the analysis. In this study, most of our samples were
from late-stage EOC and we found that a high level of expression of
CD44 was correlated with tumour grade, clinical stage, residual
tumour, relapse and ascites, but with no difference in histological
type. Our results support the fact that CD44 is involved in EOC
progression and metastasis.
Development of MDR1-mediated drug resistance results in
failure of treatment in cancer. MDR1 is expressed in stem cells and
CSCs, and thus is speculated to not only act as transporters
pumping antitumour drugs out of cells (van Herwaarden et al,
2003) but to also play a role in the maturation and differentiation
of these stem cells (Hadnagy et al, 2006). Xing et al (2007) recently
reported that knock down of P-glycoprotein reverses taxol
resistance in ovarian cancer multicellular spheroids. An increased
expression of MDR1 was found to be associated with an
unfavourable prognosis of ovarian cancer in some studies
(Materna et al, 2004; Penson et al, 2004), but not in others
(Yokoyama et al, 1999; Ozalp et al, 2002). These inconsistent
results suggest that it is necessary to further investigate the
correlation of MDR1 expression with ovarian cancer prognosis
using a relatively large number of ovarian cancer tissues before
chemotherapy. The large variation of MDR1 expression from study
to study may be attributed to the different methodologies used in
the assessment of MDR1 expression or to the different stages of
ovarian cancer in the analysis. In our study, we analysed only
primary tumour samples in the late stage of patients before any
drug treatment. Our results demonstrated that a high level of
expression of MDR1 was correlated with tumour grade, clinical
stage, residual tumour, relapse and ascites, but with no difference
in histological type. Our results support the fact that MDR1 is also
involved in EOC progression and metastasis.
In this study, we found an overexpression of uPA, CD44 and
MDR1 and a colocalisation of uPA and CD44, uPA and MDR1,
CD44 and MDR1 in cancer cells and stromal cells from most
primary tumours and matched metastatic lesions, and further
confirm the finding in EOC cell lines. No change in uPA, CD44 and
MDR1 expression was observed during the metastatic process,
whereas others have observed a downregulation of CD44 during
tumour progression in mice (Yeo et al, 1996) and in human ascitic
tumour cells (Ross et al, 2001). These results suggest that CD44
expression may be regulated in different microenviroments during
Table 4 Clinicopathological characteristics associated with uPA, CD44 and MDR1 expression in primary EOCs
No. of uPA, CD44 and MDR1 intensity/total no. (%)
UPA CD44 MDR1
Variable LEG HEG P-value* LEG HEG P-value* LEG HEG P-value*
Tumour grade
Low (1) 88% (16/18) 11% (2/18) o0.0001 94% (17/18) 6% (1/18) o0.0001 100% (18/18) 0% (0/18) o0.0001
High (2–3) 15% (15/102) 85% (87/102) 28% (29/102) 72% (73/102) 26% (26/102) 74% (76/102)
FIGO stage
Low (I–II) 41% (14/34) 59% (20/34) 0.016 59% (20/34) 41% (14/34) 0.004 53% (18/34) 47% (16/34) 0.020
High (III–IV) 20% (17/86) 80% (69/86) 30% (26/86) 70% (60/86) 30% (26/86) 70% (60/86)
Histology
Serous 23% (16/70) 77% (54/70) 0.378 43% (30/70) 57% (40/70) 0.228 39% (27/70) 61% (43/70) 0.608
Non-serous 30% (15/50) 70% (35/50) 32% (16/50) 68% (34/50) 34% (17/50) 66% (33/50)
Residual tumour
No 38% (26/68) 62% (42/68) 0.004 50% (34/68) 50% (34/68) 0.003 47% (32/68) 53% (36/68) 0.007
Yes 10% (5/52) 90% (47/52) 23% (12/52) 77% (40/52) 23% (12/52) 77% (40/52)
Relapse
No 12% (4/33) 88% (29/33) 0.035 18% (6/33) 82% (27/33) 0.005 18% (6/33) 82% (27/33) 0.014
Yes 31% (27/87) 69% (60/87) 46% (40/87) 54% (47/87) 44% (38/87) 56% (49/87)
Ascites
o500ml 9% (2/22) 91% (20/22) 0.047 18% (4/22) 82% (18/22) 0.032 18% (4/22) 82% (18/22) 0.047
X500ml 30% (29/98) 70% (69/98) 43% (42/98) 57% (56/98) 41% (40/98) 59% (58/98)
HEG¼high-expression group; LEG¼low-expression group. *w
2-test, Po0.05 significant.
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scancer metastasis. Our results indicate that overexpression of
uPA, CD44 and MDR1 may involve EOC metastases and
that cancer clones that escape from primary tumours do not
lose these antigens. The functional interaction between CD44 and
P-glycoprotein is one step in a complex molecular organisation
that results in the concomitant phenotype of MDR1, in increased cell
migration, in vitro invasion and metastasis (Miletti-Gonzalez et al,
2005); moreover, the colocalisation of uPA with CD44 or MDR1 was
found in this study, suggesting that it is possible that both uPA and
CD44 concomitantly regulate MDR1 expression during EOC for drug
resistance. The exact mechanism in th i sr e g u l a t i o ni nE O Cm e t a s t a s i s
is still unclear and needs to be investigated in future study. Given that
uPA and CD44 colocalise with MDR1-positive cells in EOC samples, it
could be a useful therapeutic target for therapy in this disease to
overcome drug resistance in the late stage of metastatic cancer. In our
human tissue experiments, we did not examine MRP2 expression
because this anti-MRP2 MAb does not work on paraffin-embedded
sections. The expression of MRP2 in primary and metastatic EOC cell
lines correlated with invasive markers (uPA and CD44), suggesting
that MRP2 also has an important function in EOC metastasis and
drug resistance. Targeting MRP2 is another option for late-stage and
drug-resistant EOC disease.
We have shown that treatment with
213Bi-labelled PAI2
(targeting membrane-bund uPA) inhibits single EOC cells and
spheroid growth in vitro (Song et al, 2006). Recently, a uPA-
derived peptide, A6, which in animal models reduced tumour
growth, metastasis and angiogenesis, alone or in combination with
other therapies, was evaluated in a phase I clinical trial in patients
with gynaecological cancers, especially OC. This study showed the
safety of A6 and some clinical potential (Berkenblit et al, 2005).
Banzato et al (2008) have recently reported that a paclitaxel-
hyaluronan bioconjugate (ONCOFID-P) interacted with CD44,
could target IGROV-1 and OVCAR-3 xenografts after i.p.
administration and show promise in future clinical trial.
A combination therapy targeting uPA and CD44 may be an
effective control of metastatic EOC disease. In addition, targeting
uPA or CD44 may provide additive or synergistic treatment
benefits if used in combination with conventional therapeutics
(chemotherapy or radiation), in particular in late-stage, metastatic,
drug-resistance EOC, for which potent conventional regimens
already exist.
In summary, we have shown for the first time that a
coexpression of uPA and CD44 with MDR markers was found in
all primary and metastatic cell lines, in most primary and matched
metastatic lesions of EOC, and the overexpression of uPA, CD44
and MDR1 was significantly associated with EOC progression. The
colocalisation of uPA and CD44 with MDR proteins in tumour cells
and stromal cells further highlights the importance of invasive
markers in the regulation of drug resistance in the progression of
EOC. Our results suggest that both uPA and CD44 may be potential
therapeutic targets for treating late-stage, incurable, recurrent
metastatic EOC to overcome drug resistance.
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